EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer

Liyona Kampel iD, Alexandra Dorman iD, Leonor Leider Trejo, Kateryna Krol, Robert Kalman Huber, Yakov Kravchenko, Yafit Antebi, Genady Shendler, Ben-Zion Joshua, Eran Alon, Anton Warshavsky, Gilad Horowitz und 3 weitere

European Thyroid Journal · 01.06.2026 · 15 (3)

DOI: 10.1530/etj-25-0394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, online erschienen am 24.04.2026. Verfasst von Liyona Kampel und 14 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Otolaryngology, Head & Neck Surgery and Maxillofacial Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Neoadjuvant therapies for locally advanced differentiated thyroid cancer (DTC) aim to downstage disease and thereby reduce the extent of surgical resection without compromising oncologic results. Understanding the histopathologic changes induced by these therapies and their correlation with radiologic response may refine surgical planning and guide optimal treatment protocols.

Objective

To characterize the histopathologic effects of neoadjuvant therapies on locally advanced DTC and evaluate their association with radiologic response and surgical outcomes.

Methods

This is a retrospective case series of patients with initially unresectable, locally advanced DTC treated with neoadjuvant therapies, lenvatinib or dabrafenib/trametinib. All patients underwent comprehensive clinical, radiologic, and histopathologic evaluation before and after neoadjuvant therapy. Histopathologic response was assessed on resection specimens using hematoxylin–eosin staining and immunohistochemistry staining for CD3, CD31, and ERG. The primary outcomes were histopathologic response, including tumor fibrosis, tumor necrosis, vascular density, and immune cell infiltration. Secondary outcomes included radiologic response, surgical feasibility, and perioperative morbidity.

Results

All nine patients achieved sufficient tumor regression to allow surgical resection. Histopathology demonstrated therapy-induced tumor fibrosis and necrosis as the predominant changes. Lenvatinib-treated tumors exhibited marked vascular remodeling, reduced microvessel density, and prominent lymphocytic infiltration, whereas BRAF-targeted therapy primarily induced tumor fibrosis without similar vascular or immune changes. The neoadjuvant therapy was well tolerated and did not increase surgical morbidity.

Conclusion

Neoadjuvant therapy facilitated R0 resection of locally advanced DTC. Lenvatinib induced vascular remodeling and immune infiltration, in contrast to fibrosis primarily seen with dabrafenib/trametinib. These histologic differences may have implications for future therapeutic decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsNeoadjuvant TherapyHumansQuinolinesFemalePhenylurea CompoundsImidazolesRetrospective StudiesMaleMiddle AgedOximesPyrimidinonesAdultTreatment OutcomePathologic Complete ResponseAntineoplastic Combined Chemotherapy ProtocolsPyridones

Stichwörter der Autor:innen

differentiated thyroid cancerpathologic responsetyrosine kinase inhibitor

Substanzen

QuinolinesPhenylurea CompoundsImidazolesdabrafeniblenvatinibOximesPyrimidinonestrametinibPyridones

Autor:innen und Institutionen

  • The Department of Otolaryngology, Head & Neck Surgery and Maxillofacial Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel.
  • The Institute of Pathology and Cancer Research, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Pathology Institute, Sheba Medical Center, Ramat Gan, Israel.
  • Patho-Lab, Assuta Medical Center, Tel Aviv, Israel.
  • Pathology Institute, Barzilai Medical Center, Ashkelon, Israel.

ORCID-Profile: Liyona Kampel, Alexandra Dorman, Inbar Finkel

Zitieren

APA

Kampel, L., Dorman, A., Trejo, L. L., Krol, K., Huber, R. K., Kravchenko, Y., Antebi, Y., Shendler, G., Joshua, B. Z., Alon, E., Warshavsky, A., Horowitz, G., Shilo, S., Muhanna, N., & Finkel, I. (2026). Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer. European Thyroid Journal, 15(3). https://doi.org/10.1530/etj-25-0394

Vancouver

Kampel L, Dorman A, Trejo LL, Krol K, Huber RK, Kravchenko Y, et al. Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer. European Thyroid Journal. 2026;15(3). doi:10.1530/etj-25-0394

BibTeX
@article{Kampel2026,
  author = {Kampel, Liyona and Dorman, Alexandra and Trejo, Leonor Leider and Krol, Kateryna and Huber, Robert Kalman and Kravchenko, Yakov and Antebi, Yafit and Shendler, Genady and Joshua, Ben-Zion and Alon, Eran and Warshavsky, Anton and Horowitz, Gilad and Shilo, Shahaf and Muhanna, Nidal and Finkel, Inbar},
  title = {Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer},
  journal = {European Thyroid Journal},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1530/etj-25-0394}
}
Kostenlos starten →